Alzheimer's Agitation Non-Antipsychotic Drug Therapy Market Global Report 2026

The alzheimer's agitation non-antipsychotic drug therapy market size has grown rapidly in recent years. It will grow from $5.09 billion in 2025 to $5.85 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to rising prevalence of alzheimer's disease globally, increasing geriatric population growth, growing awareness regarding behavioral symptoms in dementia care, expansion of neurological research activities, increasing concerns regarding antipsychotic related adverse effects.

The alzheimer's agitation non-antipsychotic drug therapy market size is expected to see rapid growth in the next few years. It will grow to $9.98 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to growing investments in neurodegenerative disease drug development, increasing demand for precision medicine approaches, rising clinical research for novel neurobehavioral therapies, expansion of home based dementia care services, increasing regulatory support for safer treatment alternatives. Major trends in the forecast period include increasing development of safer alternatives to antipsychotic therapies, growing focus on targeted neurobehavioral symptom management, rising adoption of multimodal therapeutic approaches for agitation treatment, increasing research on neurotransmitter pathway modulation therapies, expansion of clinical trials for novel central nervous system therapies.

The increasing prevalence of Alzheimer's disease is expected to drive the growth of the Alzheimer's agitation non-antipsychotic drug therapy market going forward. Alzheimer’s disease is a progressive neurodegenerative condition that gradually affects memory, cognitive abilities, and behavior due to the deterioration and loss of brain cells. The growing prevalence of Alzheimer’s disease is attributed to rising life expectancy, as an expanding elderly population increases the number of individuals reaching age groups with a higher risk of developing the condition. Alzheimer’s agitation non-antipsychotic drug therapy helps manage behavioral and psychological symptoms associated with Alzheimer’s disease, enhancing patient care, improving quality of life, and supporting better long-term care outcomes for the increasing patient population. For instance, in December 2025, according to the Australian Government, an Australian-based government department, approximately 25,000 people in Australia were living with dementia, including nearly 266,000 women and 159,000 men, representing around 16 cases per 1,000 Australians (19 per 1,000 women and 12 per 1,000 men). Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the Alzheimer's agitation non-antipsychotic drug therapy market.

The increasing investments in research and development are expected to drive the growth of the Alzheimer's agitation non-antipsychotic drug therapy market going forward. Research and development investments refer to the allocation of financial resources by governments, pharmaceutical companies, and academic organizations toward the discovery, development, and clinical evaluation of new therapeutic solutions. The growth in R&D investments is primarily fueled by the rising global burden of Alzheimer's disease, as an increasing aging population expands the number of patients requiring targeted therapies, creating greater demand for effective non-antipsychotic treatment approaches. Increased R&D funding supports the discovery and clinical validation of innovative non-antipsychotic compounds that specifically target agitation symptoms in Alzheimer’s patients, strengthening the therapeutic pipeline and enabling the introduction of new treatment options. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, representing a rise of $48 billion. Therefore, increasing research and development investments are driving the growth of the Alzheimer's agitation non-antipsychotic drug therapy market.

Major companies operating in the Alzheimer's agitation non-antipsychotic drug therapy market are focusing on developing advanced non-antipsychotic treatments to manage agitation symptoms associated with Alzheimer's disease while reducing the safety risks associated with conventional antipsychotic medications. Non-antipsychotic therapies are treatments that address agitation through alternative neurological pathways without using antipsychotic mechanisms, potentially providing improved safety and tolerability for elderly patients. For instance, in April 2026, Axsome Therapeutics, a US-based biopharmaceutical company, received U.S. FDA approval for Auvelity (dextromethorphan-bupropion) for treating agitation associated with dementia caused by Alzheimer’s disease. The approval marked the introduction of the first FDA-approved non-antipsychotic therapy for this indication, providing a new treatment approach for managing agitation symptoms. The therapy acts on NMDA and sigma-1 receptors, expanding available treatment options for patients and caregivers.

Major companies operating in the alzheimer's agitation non-antipsychotic drug therapy market report are Axsome Therapeutics Inc., Bristol Myers Squibb Company, Suven Life Sciences Limited, IGC Pharma Inc., Exciva GmbH, Neumora Therapeutics Inc.

North America was the dominating region in the alzheimer's agitation non-antipsychotic drug therapy market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the alzheimer's agitation non-antipsychotic drug therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alzheimer's agitation non-antipsychotic drug therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.